Lyell Immunopharma, INC 8-K filings

NASDAQ

6 May 2024

LYEL

8-K: Lyell Immunopharma Reports Q1 2024 Financial Results and Provides Clinical Pipeline Update

Lyell Immunopharma announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position to support operations into 2027.

NASDAQ

28 Feb 2024

LYEL

Lyell Immunopharma, INC

8-K: Lyell Immunopharma Reports Full Year 2023 Results and Provides Clinical Pipeline Update

Lyell Immunopharma announced its full year 2023 financial results and provided updates on its clinical programs, highlighting progress in its CAR T-cell and TIL therapies.